# Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

> **NCT03489343** · PHASE1 · COMPLETED · sponsor: **Symphogen A/S** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Cancer
- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** Sym023

## Key facts

- **NCT ID:** NCT03489343
- **Lead sponsor:** Symphogen A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-24
- **Primary completion:** 2020-06-03
- **Final completion:** 2020-06-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03489343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03489343, "Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03489343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*